- cafead   Jul 07, 2020 at 10:32: AM
via Obseva trailed the results from its second pivotal uterine fibroid study a week ago, and then failed to include crucial data in the press release, forcing investors to wait for a conference call for the big reveal. Those cynical about such tactics were proved correct: linzagolix’s profile versus the competition now looks even more questionable than before.
article source
article source